Movement disorders in the older patient: Differential diagnosis and general management

Cleveland Clinic Journal of Medicine

Volumn 72, Issue SUPPL.3, 2004, Pages

  Baron, Mark S ^a  

^a HUNTER HOLMES MCGUIRE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; DIFFERENTIAL DIAGNOSIS; HUMAN; MOTOR DYSFUNCTION; REVIEW;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MOVEMENT DISORDERS;

EID: 84884580587     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.Suppl_3.S38     Document Type: Article

References (125)

1. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Arch Neurol 1992; 49:494-497.
2. Strickland D, Bertoni JM. Parkinson's prevalence estimated by a state registry. Mov Disord 2004; 19:318-323.
3. Muller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology 2000; 55:888-891.
4. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MM, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997; 48:1277-1281.
5. Muller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 2000; 55:888-891.
6. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995; 45:1041-1051.
7. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999; 52:115-119.
8. Tanner CM, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins. Neurology 2002; 58:581-588.
9. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001; 50:56-63.
10. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60:1059-1064.
11. Pearce RKB, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than Ldopa in the MPTP-treated marmoset. Mov Disord 1998; 13:234-241.
12. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342:1484-1491.
13. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology 1991; 41(2 pt 1):168-173.
14. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate- release and controlled-release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. Eur Neurol 1997; 37:23-27.
15. Lieberman AN, Neophytides A, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 1983; 37:95-108.
16. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9:431-436.
17. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49:1060-1065.
18. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999; 53:364-370.
19. Mizuno Y, Yanagisawa N, Kuno S, et al, Japanese Pramipexole Study Group. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord 2003; 18:1149-1156.
20. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179-1183.
21. Paus S, Brecht HM, Köster J, Seeger G, Klockgether T, Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18:659-667.
22. Marjama-Lyons J, Koller W. Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 2000; 16:273-278.
23. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51:1309-1314.
24. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M, NOMESAFE Study Group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003; 10:137-146.
25. Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 2001; 24:295-299.
26. Keating GM, Lyseng-Williamson KA. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. CNS Drugs 2005; 19:165-184.
27. Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin Ther 2005; 27:58-63.
28. Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004; 62(suppl 4):S12-S17.
29. Thomas A, Iacono D, Luciano AL, Armellino K, DiIorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:141-143.
30. Baron MS, Dalton WB. Quetiapine as a treatment for dopaminergic- induced dyskinesias in Parkinson's disease. Mov Disord 2003; 18:1208-1209.
31. Jaskiw GE, Thyrum PT, Fuller MA, Arvanitis LA, Yeh C. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders. Clin Pharmacokinet 2004; 43:1025-1035.
32. Aarsland D, Andersen K, Larsen JP, Lolk A. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60:387-392.
33. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54:363-375.
34. Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease-a retrospective comparison. Acta Neurol Scand 1995; 91:98-102.
35. Ramig LO, Sapir S, Countryman S, et al. Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up. J Neurol Neurosurg Psychiatry 2001; 71:493-498.
36. The Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345:956-963.
37. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354:1771-1775.
38. Tison F, Yekhlef F, Chrysostome V, Sourgen C. Prevalence of multiple system atrophy. Lancet 2000; 355:495-496.
39. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994; 117:835-845.
40. Ben-Shlomo Y, Wenning G, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997; 48:384-393.
41. Testa D, Monza D, Ferrarini M, Soliveri P, Girotti F, Filippini G. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci 2001; 22:247-251.
42. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125:1070-1083.
43. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989; 94:79-100.
44. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163:94-98.
45. Stocchi F, Brusa L. Cognition and emotion in different stages and subtypes of Parkinson's disease. J Neurol 2000; 247(suppl 2):II114-II121.
46. Kraft E, Trenkwalder C, Auer DP. T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology 2002; 59:1265-1267.
47. Seppi K, Schocke MFH, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60:922-927.
48. Chou KL, Forman MS, Trojanowski JQ, Hurtig HI, Baltuch GH. Subthalamic nucleus deep brain stimulation in a patient with levodopa- responsive multiple system atrophy. Case report. J Neurosurg 2004; 100:553-556.
49. Tarsy D, Apetauerova D, Ryan P, Norregaard T. Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy. Neurology 2003; 61:247-249.
50. Yamaguchi M, Arai K, Asahina M, Hattori T. Laryngeal stridor in multiple system atrophy. Eur Neurol 2003; 49:154-159.
51. Iranzo A, Santamaria J, Tolosa E, et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004; 63:930-932.
52. Higo R, Tayama N, Watanabe T, Nitou T, Ugawa Y. Videofluoroscopic and manometric evaluation of swallowing function in patients with multiple system atrophy. Ann Otol Rhinol Laryngol 2003; 112:630-636.
53. Santacruz P, Uttl B, Litvan I, Grafman J. Progressive supranuclear palsy: a survey of the disease course. Neurology 1998; 50:1637-1647.
54. Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124:1438-1449.
55. De Bruin VM, Lees AJ. Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: a review of 90 pathologically verified cases. Mov Disord 1994; 9:381-389.
56. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60:615-620.
57. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson- Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47:1-9.
58. Vidailhet M, Rivaud S, Gouider-Khouja N, et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994; 35:420-426.
59. Mega MS, Masterman DL, Benson DF, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996; 47:1403-1409.
60. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003; 74:720-724.
61. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000; 54:1050-1058.
62. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004; 62:181-187.
63. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003:CD003672.
64. Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998; 10:227-229.
65. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63:513-515.
66. Caplan LR. Binswanger's disease-revisited. Neurology 1995; 45:626-633.
67. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1:426-436.
68. Awad IA, Spetzler RF, Hodak JA, Awad CA, Carey R. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. I. Correlation with age and cerebrovascular risk factors. Stroke 1986; 17:1084-1089.
69. van Swieten JC, Geyskes GG, Derix MMA, et al. Hypertension in the elderly is associated with white matter lesions and cognitive decline. Ann Neurol 1991; 30:825-830.
70. Blass JP, Hoyer S, Nitsch R. A translation of Otto Binswanger's article, 'The delineation of the generalized progressive paralyses.' 1894. Arch Neurol 1991; 48:961-972.
71. DeReuck J, Crevits L, De Coster W, Sieben G, vander Eecken H. Pathogenesis of Binswanger chronic progressive subcortical encephalopathy. Neurology 1980; 30:920-928.
72. Bennett DA, Wilson RS, Gilley DW, Fox JH. Clinical diagnosis of Binswanger's disease. J Neurol Neurosurg Pyschiatry 1990; 53:961-965.
73. Caplan LR, Schoene WC. Clinical features of subcortical arteriosclerotic encephalopathy (Binswanger disease). Neurology 1978; 28:1206-1215.
74. Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov Disord 1987; 2:1-8.
75. Traykov L, Baudic S, Raoux N, et al. Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia. J Neurol Sci 2005; 229-230:75-79.
76. Hebb AO, Cusimano MD. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. Neurosurgery 2001; 49:1166-1184.
77. Savolainen S, Hurskainen H, Paljärvi L, Alafuzoff I, Vapalahti M. Five-year outcome of normal pressure hydrocephalus with or without a shunt: predictive value of the clinical signs, neuropsychological evaluation and infusion test. Acta Neurochir (Wien) 2002; 144:515-523.
78. Adams RD, Fisher CM, Hakim S, Ojemann RG, Sweet WH. Symptomatic occult hydrocephalus with "normal" cerebrospinal-fluid pressure: a treatable syndrome. N Engl J Med 1965; 273:117-126.
79. Thomsen AM, Børgesen SE, Bruhn P, Gjerris F. Prognosis of dementia in normal-pressure hydrocephalus after a shunt operation. Ann Neurol 1986; 20:304-310.
80. Malm J, Kristensen B, Karlsson T, Fagerlund M, Elfverson J, Ekstedt J. The predictive value of cerebrospinal fluid dynamic tests in patients with the idiopathic adult hydrocephalus syndrome. Arch Neurol 1995; 52:783-789.
81. Di Lauro L, Mearini M, Bollati A. The predictive value of 5 days CSF diversion for shunting in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 1986; 49:842-843.
82. Haan J, Thomeer RTWM. Predictive value of temporary external lumbar drainage in normal pressure hydrocephalus. Neurosurgery 1988; 22:388-391.
83. Chen IH, Huang CI, Liu HC, Chen KK. Effectiveness of shunting in patients with normal pressure hydrocephalus predicted by temporary, controlled-resistance, continuous lumbar drainage: a pilot study. J Neurol Neurosurg Psychiatry 1994; 57:1430-1432.
84. Symon L, Dorsch NWC. Use of long-term intracranial pressure measurement to assess hydrocephalic patients prior to shunt surgery. J Neurosurg 1975; 42:258-273.
85. Krauss JK, Halve B. Normal pressure hydrocephalus: survey on contemporary diagnostic algorithms and therapeutic decision-making in clinical practice. Acta Neurochir (Wien) 2004; 146:379-388.
86. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord 1998; 13:5-10.
87. Rautakorpi I, Takala J, Marttila RJ, Sievers K, Rinne UK. Essential tremor in a Finnish population. Acta Neurol Scand 1982; 66:58-67.
88. Rajput A, Robinson CA, Rajput AH. Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology 2004; 62:932-936.
89. Tanner CM, Goldman SM, Lyons KE, et al. Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology. Neurology 2001; 57:1389-1391.
90. Lorenz D, Frederiksen H, Moises H, Kopper F, Deuschl G, Christensen K. High concordance for essential tremor in monozygotic twins of old age. Neurology 2004; 62:208-211.
91. Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord 1997; 12:859-864.
92. Gulcher JR, Jonsson P, Kong A, et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet 1997; 17:84-87.
93. Deuschl G, Wenzelburger R, Löffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction: clinical and kinematic analysis of intention tremor. Brain 2000; 123:1568-1580.
94. Pinto AD, Lang AE, Chen R. The cerebellothalamocortical pathway in essential tremor. Neurology 2003; 60:1985-1987.
95. Brennan KC, Jurewicz EC, Ford B, Pullman SL, Louis ED. Is essential tremor predominantly a kinetic or a postural tremor? A clinical and electrophysiological study. Mov Disord 2002; 17:313-316.
96. Elble RJ. Diagnostic criteria for essential tremor and differential diagnosis. Neurology 2000; 54(11 suppl 4):S2-S6.
97. Lombardi WJ, Woolston DJ, Roberts JW, Gross RE. Cognitive deficits in patients with essential tremor. Neurology 2001; 57:785-790.
98. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998; 121:561-579.
99. Gorman WP, Cooper R, Pocock P, Campbell MJ. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry 1986; 49:64-68.
100. Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology 1986; 36:121-124.
101. Sullivan KL, Hauser RA, Zesiewicz TA. Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004; 10:250-258.
102. Jefferson D, Jenner P, Marsden CD. Beta-adrenoreceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry 1979; 42:904-909.
103. Leigh PN, Marsden CD, Twomey A, Jefferson D. Beta-adrenoceptor antagonists and essential tremor. Lancet 1981; 1:1106.
104. Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. Neurology 1988; 38:241-243.
105. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology 2002; 59:132-134.
106. Gatto EM, Roca MCU, Raina G, Micheli F. Low doses of topiramate are effective in essential tremor: a report of three cases. Clin Neuropharmacol 2003; 26:294-296.
107. Lyons KE, Pahwa R. Deep brain stimulation and essential tremor. J Clin Neurophysiol 2004; 21:2-5.
108. Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003; 9:16-27.
109. Baldessarini RJ, Cole JO, Davis JM, et al. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. Am J Psychiatry 1980; 137:1163-1172.
110. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999; 156:309-311.
111. Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155:1521-1528.
112. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157:1150-1155.
113. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004; 65:696-701.
114. Bacher NM, Lewis HA. Reserpine and tardive dyskinesia. Am J Psychiatry 1984; 141:719.
115. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999; 156:1279-1281.
116. Trottenberg T, Paul G, Meissner W, Maier-Hauff K, Taschner C, Kupsch A. Pallidal and thalamic neurostimulation in severe tardive dystonia. J Neurol Neurosurg Psychiatry 2001; 70:557-559.
117. Schrader C, Peschel T, Petermeyer M, Dengler R, Hellwig D. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord 2004; 19:583-585.
118. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994; 17:739-743.
119. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the 'Night-Walkers' survey. Neurology 1996; 46:92-95.
120. Allen RP, Picchietti D, Hening WA, et al, for the International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101-119.
121. Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160:2137-2141.
122. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996; 19:205-213.
123. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002; 59:1573-1579.
124. Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow- up on restless legs syndrome patients treated with opioids. Mov Disord 2001; 16:1105-1109.
125. Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord 2005; 20:345-348